Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$5.03 +3.7%	$5.20	$3.79 ▼ $14.60	$243M	-0.87	1.47 million shs	899,689 shs
DBVT DBV Technologies	$9.21 +6.6%	$9.22	$2.20 ▼ $12.78	$236.65M	-0.63	190,045 shs	21,083 shs
ONCY Oncolytics Biotech	$0.72 +4.8%	$0.52	$0.33 ▼ $1.53	$64.77M	0.71	645,314 shs	1.88 million shs
TVRD Tvardi Therapeutics	$25.21 -7.0%	$0.00	$8.13 ▼ $34.31	$253.77M	0.25	75,366 shs	51,032 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+3.71%	+2.24%	-10.18%	-15.46%	-11.91%
DBVT DBV Technologies	+6.60%	-6.50%	-0.86%	+48.55%	+94.32%
ONCY Oncolytics Biotech	+4.35%	-2.70%	+79.55%	+20.00%	-30.77%
TVRD Tvardi Therapeutics	-7.01%	-1.48%	-24.50%	+2,520,999,900.00%	+2,520,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.4512 of 5 stars	3.5	3.0	0.0	0.0	2.5	0.8	0.6
DBVT DBV Technologies	3.459 of 5 stars	3.3	5.0	0.0	0.0	3.2	2.5	0.6
ONCY Oncolytics Biotech	1.5465 of 5 stars	3.4	2.0	0.0	0.0	2.9	0.0	0.0
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$21.00	317.50% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	60.15% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	501.85% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$71.50	183.62% Upside

Current Analyst Ratings Breakdown

Latest ONCY, TVRD, DBVT, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/12/2025	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/21/2025	TVRD Tvardi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,100.03	N/A	N/A	$1.41 per share	3.57
DBVT DBV Technologies	$4.15M	60.79	N/A	N/A	$1.42 per share	6.49
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A
TVRD Tvardi Therapeutics	$7.14M	33.05	N/A	N/A	($3.02) per share	-8.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	8/12/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	7/30/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-710.04%	-79.00%	N/A

Latest ONCY, TVRD, DBVT, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
DBVT DBV Technologies	N/A	0.72	0.72
ONCY Oncolytics Biotech	N/A	3.20	3.20
TVRD Tvardi Therapeutics	N/A	32.48	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
DBVT DBV Technologies	71.74%
ONCY Oncolytics Biotech	6.82%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
DBVT DBV Technologies	1.44%
ONCY Oncolytics Biotech	0.10%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
ONCY Oncolytics Biotech	30	94.28 million	94.19 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.36 million	9.07 million	N/A

ONCY, TVRD, DBVT, and CADL Headlines

Recent News About These Companies

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler

June 12, 2025 | marketbeat.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, TVRD, DBVT, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$5.03 +0.18 (+3.71%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$5.01 -0.02 (-0.30%)

As of 08:00 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.21 +0.57 (+6.60%)

Closing price 06/26/2025 03:53 PM Eastern

Extended Trading

$9.13 -0.08 (-0.83%)

As of 07:27 AM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Oncolytics Biotech NASDAQ:ONCY

$0.72 +0.03 (+4.80%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.79 +0.07 (+9.44%)

As of 08:02 AM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Tvardi Therapeutics NASDAQ:TVRD

$25.21 -1.90 (-7.01%)

As of 06/26/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time